Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 9/20 | 0.72 |
| ▸ | CES1 | P23141 | 9/20 | 0.72 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28578490 | 0.85 | CES2 (0.79) | CES2CES1PTGS2ALDH1A1NAAA | |
| SCHEMBL7219046 | 0.84 | CES1 (1.00) | CES2CES1PTGS2ALDH1A1NAAA | |
| SCHEMBL27480440 | 0.81 | CES2 (0.68) | CES2CES1PTGS2ALDH1A1NAAA | |
| SCHEMBL28378143 | 0.79 | CES2 (0.80) | CES2CES1PTGS2NAAAL3MBTL1 | |
| Valerophenone SCHEMBL50014 | 0.79 | L3MBTL1 (0.72) | CES2CES1PTGS2L3MBTL1LMNA | |
| Valerophenone SCHEMBL9725402 | 0.79 | L3MBTL1 (0.72) | CES2CES1PTGS2L3MBTL1LMNA | |
| Valerophenone SCHEMBL5615151 | 0.79 | L3MBTL1 (0.72) | CES2CES1PTGS2L3MBTL1LMNA | |
| SCHEMBL7219754 | 0.78 | CES2 (1.00) | CES2CES1PTGS2NAAAL3MBTL1 | |
| Benzil SCHEMBL337491 | 0.78 | CES2 (0.74) | CES2CES1ALDH1A1LMNAMAPT | |
| SCHEMBL5698577 | 0.78 | CES2 (0.81) | CES2CES1PTGS2NAAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981008-B2 | Apolipoprotein A-I mimics | CERENIS THERAPEUTICS HOLDING SA (FR) | 2018-05-29 | — | — | US | disclosed |
| EP-2939683-B1 | Apolipoprotein A-I Mimics | CERENIS THERAPEUTICS HOLDING SA (FR) | 2017-01-04 | — | — | EP | disclosed |
| US-20160324923-A1 | APOLIPOPROTEIN A-I MIMICS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2016-11-10 | — | — | US | disclosed |
| US-9388232-B2 | Apolipoprotein A-I mimics | CERENIS THERAPEUTICS HOLDING SA (FR) | 2016-07-12 | — | — | US | disclosed |
| EP-2939683-A1 | Apolipoprotein A-I Mimics | Cerenis Therapeutics Holding SA (FR) | 2015-11-04 | — | — | EP | disclosed |
| EP-2396017-B1 | APOLIPOPROTEIN A-I MIMICS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2015-07-01 | — | — | EP | disclosed |
| US-20150141330-A1 | APOLIPOPROTEIN A-I MIMICS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2015-05-21 | — | — | US | disclosed |
| CN-104530223-A | Apolipoprotein A-I mimics | CERENIS THERAPEUTICS SA | 2015-04-22 | — | — | CN | disclosed |
| US-8993597-B2 | Apolipoprotein A-I mimics | CERENIS THERAPEUTICS HOLDING SA (FR) | 2015-03-31 | — | — | US | disclosed |
| CN-102395375-B | Apolipoprotein A-I mimetics | CERENIS THERAPEUTICS SA | 2015-01-14 | — | — | CN | disclosed |
| CN-102395375-A | Apolipoprotein A-I mimetics | CERENIS THERAPEUTICS SA | 2012-03-28 | — | — | CN | disclosed |
| EP-2396017-A1 | APOLIPOPROTEIN A-I MIMICS | Cerenis Therapeutics SA (FR) | 2011-12-21 | — | — | EP | disclosed |
| US-7994120-B2 | Administering to a subject an apolipoprotein-sphingomyelin complex comprising an apolipoprotein and the lipid sphingomyelin in an amount effective to achieve a serum level of free or complexed apolipoprotein in the range of 30 mg/dL to 300 mg/dL after administration; treatment of cardiovascular disease | PFIZER, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-20100267631-A1 | APOLIPOPROTEIN A-I MIMICS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2010-10-21 | — | — | US | disclosed |
| WO-2010093918-A1 | APOLIPOPROTEIN A-I MIMICS | CERENIS THERAPEUTICS SA (FR) | 2010-08-19 | — | — | WO | disclosed |
| EP-1511508-A4 | METHOD OF TREATING DYSLIPIDEMIC DISORDERS | ESPERION THERAPEUTICS INC (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20080269111-A1 | METHOD OF TREATING DYSLIPIDEMIC DISORDER | PFIZER INC | 2008-10-30 | — | — | US | disclosed |
| EP-1511508-A2 | METHOD OF TREATING DYSLIPIDEMIC DISORDERS | Esperion Therapeutics Inc. (US) | 2005-03-09 | — | — | EP | disclosed |
| US-20040067873-A1 | Method of treating dyslipidemic disorders | PFIZER INC. | 2004-04-08 | — | — | US | disclosed |
| WO-2003096983-A2 | METHOD OF TREATING DYSLIPIDEMIC DISORDERS | ESPERION THERAPEUTICS, INC. (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267631-A1 | APOLIPOPROTEIN A-I MIMICS | APOB, APOL1, LIPG | CES2 2754/4885CES1 249/4885PTGS2 3987/4885 |
| US-20160324923-A1 | APOLIPOPROTEIN A-I MIMICS | APOB, APOL1, LIPG | CES2 2754/4885CES1 249/4885PTGS2 3987/4885 |
| US-20150141330-A1 | APOLIPOPROTEIN A-I MIMICS | APOB, APOL1, LIPG | CES2 2754/4885CES1 249/4885PTGS2 3987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.